DOCSLIB.ORG

Imm Catalog.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Imm Catalog.Pdf $ Gene Symbol A B 3 C 4 D 9 E 10 F 11 G 12 H 13 I 14 J. K 17 L 18 M 19 N 20 O. P 22 R 26 S 27 T 30 U 32 V. W. X. Y. Z 33 A ® ® Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera A1CF 29974 ● ● ADAMTS13 11093 ● ● ● ● ● A2M 2 ● ● ● ● ● ● ADAMTS20 80070 ● AACS 65985 ● ● ● ADAMTS5 11096 ● ● ● AANAT 15 ● ● ADAMTS8 11095 ● ● ● ● AATF 26574 ● ● ● ● ● ADAMTSL2 9719 ● AATK 9625 ● ● ● ● ADAMTSL4 54507 ● ● ABCA1 19 ● ● ● ● ● ADAR 103 ● ● ABCA5 23461 ● ● ADARB1 104 ● ● ● ● ABCA7 10347 ● ADARB2 105 ● ABCB9 23457 ● ● ● ● ● ADAT1 23536 ● ● ABCC4 10257 ● ● ● ● ADAT2 134637 ● ● ABCC5 10057 ● ● ● ● ● ADAT3 113179 ● ● ● ABCC8 6833 ● ● ● ● ADCY10 55811 ● ● ABCD2 225 ● ADD1 118 ● ● ● ● ● ● ABCD4 5826 ● ● ● ADD3 120 ● ● ● ABCG1 9619 ● ● ● ● ● ADH5 128 ● ● ● ● ● ● ABL1 25 ● ● ADIPOQ 9370 ● ● ● ● ● ABL2 27 ● ● ● ● ● ADK 132 ● ● ● ● ● ABO 28 ● ● ADM 133 ● ● ● ABP1 26 ● ● ● ● ● ADNP 23394 ● ● ● ● ABR 29 ● ● ● ● ● ADORA1 134 ● ● ACAA2 10449 ● ● ● ● ADORA2A 135 ● ● ● ● ● ● ● ACAN 176 ● ● ● ● ● ● ADORA2B 136 ● ● ACE 1636 ● ● ● ● ADRA1A 148 ● ● ● ● ACE2 59272 ● ● ADRA1B 147 ● ● ACER2 340485 ● ADRA2A 150 ● ● ACHE 43 ● ● ● ● ● ● ADRB1 153 ● ● ACIN1 22985 ● ● ● ADRB2 154 ● ● ● ● ● ACOX1 51 ● ● ● ● ● ADRB3 155 ● ● ● ● ACP5 54 ● ● ● ● ● ● ● ADRBK1 156 ● ● ● ● ACSF2 80221 ● ● ADRM1 11047 ● ● ● ● ACSF3 197322 ● ● AEBP1 165 ● ● ● ● ACSL4 2182 ● ● ● ● AEN 64782 ● ACTC1 70 ● ● AES 166 ● ● ● ● ● ● ● ACTN1 87 ● ● ● ● ● ● AFAP1L2 84632 ● ● ACTN2 88 ● AGAP2 116986 ● ● ● ACTN3 89 ● ● AGER 177 ● ● ● ● ● ● ● ● ACTN4 81 ● ● ● ● ● ● ● AGGF1 55109 ● ● ● ● ● ACVR1 90 ● ● ● ● ● AGK 55750 ● ● ● ● ● ACVR1B 91 ● ● ● ● ● ● AGPAT1 10554 ● ● ● ● ACVR1C 130399 ● ● ● ● ● ● AGPAT2 10555 ● ● ● ● ● ACVR2A 92 ● ● ● ● ● AGT 183 ● ● ● ● ● ● ● ACVR2B 93 ● ● ● ● ● ● ● AGTR1 185 ● ● ● ACVRL1 94 ● ● ● ● ● AGTR2 186 ● ● ● ADA 100 ● ● ● ● ● ● AHR 196 ● ● ● ● ● ● ● ADAD1 132612 ● ● ● AHSG 197 ● ● ● ● ● ● ● ADAD2 161931 ● ● ● AICDA 57379 ● ● ● ● ● ADAL 161823 ● ● AIF1 199 ● ● ● ● ADAM10 102 ● ● ● ● AIF1L 83543 ● ● ● ADAM11 4185 ● ● ● ● AIFM1 9131 ● ● ● ● ● ● ADAM12 8038 ● ● ● ● ● ● ● AIFM2 84883 ● ● ● ● ● ● ADAM15 8751 ● ● ● ● AIFM3 150209 ● ● ADAM17 6868 ● ● ● ● AIM2 9447 ● ● ● ● ADAM2 2515 ● ● ● ● ● ● AIMP1 9255 ● ● ● ● ADAM22 53616 ● ● AIMP2 7965 ● ● ● ADAM23 8745 ● AIPL1 23746 ● ● ● ● ● ● ● ADAM8 101 ● ● AIRE 326 ● ● ADAM9 8754 ● ● ● AKAP11 11215 ● ● ● ADAMDEC1 27299 ● ● ● ● AKAP13 11214 ● ● ● ● ● ADAMTS1 9510 ● ● ● ● AKAP17A 8227 ● ● ● ● ● ● 1. 1 A ® ® Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera AKAP4 8852 ● ● ● ● AP3B2 8120 ● AKIP1 56672 ● ● ● ● ● ● AP3D1 8943 ● ● AKIRIN2 55122 ● ● ● ● APAF1 317 ● ● ● ● ● AKR1C2 1646 ● ● ● ● ● ● ● APBA1 320 ● AKR1C3 8644 ● ● ● ● ● APBB1 322 ● ● ● ● ● AKT1 207 ● ● ● ● ● ● ● ● APC 324 ● ● ● ● ● AKT2 208 ● ● ● ● APCS 325 ● ● ● ● ● ● AKTIP 64400 ● ● ● ● ● APEX1 328 ● ● ● ● ● ● ● ALB 213 ● ● ● ● ● ● ● APH1A 51107 ● ALCAM 214 ● ● ● ● ● ● API5 8539 ● ● ● ● ALDH1A2 8854 ● ● APIP 51074 ● ● ● ALDH2 217 ● ● ● ● ● ● APITD1 378708 ● ● ● ALDH6A1 4329 ● ● ● APLP1 333 ● ● ALDOA 226 ● ● ● ● ● ● APOA1 335 ● ● ● ● ● ● ● ALDOB 229 ● ● ● ● ● ● APOA2 336 ● ● ● ● ● ● ● ALDOC 230 ● ● APOA4 337 ● ● ● ● ● ● ALG1 56052 ● ● ● ● ● APOA5 116519 ● ● ● ● ALK 238 ● ● ● APOB 338 ● ● ● ● ● ALMS1 7840 ● APOC1 341 ● ● ● ● ● ● ● ALOX12 239 ● ● ● ● ● ● ● APOC2 344 ● ● ● ● ● ● ● ALOX15B 247 ● ● ● ● ● APOC3 345 ● ● ● ● ALPL 249 ● ● ● ● ● ● ● ● APOE 348 ● ● ● ● ALX3 257 ● ● ● ● APOH 350 ● ● ● ● ● ● ● ALX4 60529 ● ● APOL2 23780 ● ● ● ● AMBN 258 ● ● APP 351 ● ● ● ● AMBP 259 ● ● ● ● ● ● APPL1 26060 ● ● ● ● ● ● AMELX 265 ● ● ● ● ● ● AQP1 358 ● ● ● ● ● AMHR2 269 ● ● ● AQP2 359 ● ● ● ● AMICA1 120425 ● ● AQP3 360 ● AMIGO2 347902 ● ● AQP4 361 ● ● ● AMIGO3 386724 ● ● AR 367 ● ● ● ● ● AMOT 154796 ● ● ● ● ● ● ● ARAF 369 ● ● ● ● ● ● AMOTL1 154810 ● ARC 23237 ● ● ● AMPH 273 ● ● ● ● ● ARF6 382 ● ● ● AMTN 401138 ● ARFGEF1 10565 ● ANGPT1 284 ● ● ● ARFGEF2 10564 ● ANGPT2 285 ● ● ARG1 383 ● ● ● ● ● ANGPT4 51378 ● ● ● ● ARG2 384 ● ● ● ● ● ● ANGPTL1 9068 ● ● ● ● ARHGAP17 55114 ● ANGPTL3 27329 ● ● ● ● ● ● ARHGAP4 393 ● ● ● ● ANGPTL4 51129 ● ● ● ● ● ● ● ● ARHGAP5 394 ● ANK1 286 ● ● ● ● ● ● ARHGDIA 396 ● ● ● ● ● ● ● ANKRD54 129138 ● ARHGDIB 397 ● ● ● ● ● ● ANLN 54443 ● ● ● ARHGDIG 398 ● ● ● ● ● ANO6 196527 ● ARHGEF11 9826 ● ● ● ANTXR1 84168 ● ● ● ● ● ARHGEF12 23365 ● ● ● ANXA1 301 ● ● ● ● ● ● ● ARHGEF16 27237 ● ● ● ANXA11 311 ● ● ● ● ● ARHGEF17 9828 ● ANXA3 306 ● ● ● ● ● ● ARHGEF18 23370 ● ● ANXA4 307 ● ● ● ● ● ● ● ARHGEF2 9181 ● ● ● ● ANXA5 308 ● ● ● ● ● ● ● ARHGEF3 50650 ● ● ● ● ● ANXA9 8416 ● ● ● ● ARHGEF4 50649 ● ● ● AOC3 8639 ● ● ● ● ● ● ● ARHGEF6 9459 ● ● ● ● ● AP1B1 162 ● ● ● ARHGEF7 8874 ● ● ● ● AP1G1 164 ● ● ARHGEF9 23229 ● ● AP1S1 1174 ● ● ● ● ARID5B 84159 ● ● ● AP1S2 8905 ● ● ● ● ARL3 403 ● ● ● AP2A1 160 ● ● ● ARL4A 10124 ● ● ● ● AP2S1 1175 ● ● ● ● ARL6 84100 ● ● ● AP3B1 8546 ● ● ● ● ● ARNT2 9915 ● ● ● ● ● 1. 2 A ® ® B Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera ARR3 407 ● ● ● ● ● BAI1 575 ● ● ARRB1 408 ● ● ● ● BAK1 578 ● ● ● ● ● ● ARRB2 409 ● ● ● ● ● ● BAMBI 25805 ● ● ● ART4 420 ● ● ● ● ● ● BARD1 580 ● ● ● ● ARVCF 421 ● ● ● BARHL1 56751 ● ● ● ● ● ● ASAH2 56624 ● BARX1 56033 ● ● ● ● ● ASB1 51665 ● BAX 581 ● ● ● ● ● ASCL1 429 ● ● ● ● ● ● BBC3 27113 ● ● ASGR1 432 ● ● BBS2 583 ● ● ASGR2 433 ● ● ● ● BBS4 585 ● ● ● ● ASNS 440 ● ● ● ● ● ● BBS7 55212 ● ● ● ● ● ● ASPN 54829 ● ● ● BBS9 27241 ● ● ASS1 445 ● ● ● ● BCAM 4059 ● ● ● ● ATF2 1386 ● ● ● ● ● ● BCAN 63827 ● ● ● ATF5 22809 ● ● ● ● ● BCAP29 55973 ● ● ● ● ● ● ● ATG12 9140 ● ● ● ● ● BCAP31 10134 ● ● ● ● ● ● ● ATG3 64422 ● ● ● ● ● BCAR1 9564 ● ● ● ● ● ● ATG5 9474 ● ● ● ● ● BCL10 8915 ● ● ● ATL1 51062 ● ● ● ● BCL11A 53335 ● ● ● ● ● ● ● ATM 472 ● ● ● ● ● BCL11B 64919 ● ATOH1 474 ● ● ● ● ● ● BCL2 596 ● ● ● ● ● ● ATP1B1 481 ● ● ● BCL2A1 597 ● ● ● ● ATP1B2 482 ● ● ● ● BCL2L1 598 ● ● ● ● ● ATP1B3 483 ● ● ● ● ● BCL2L10 10017 ● ● ● ● ● ● ATP2A1 487 ● ● ● ● ● BCL2L11 10018 ● ● ● ● ● ATP2A2 488 ● ● BCL2L12 83596 ● ● ● ● ● ● ATP2A3 489 ● ● ● BCL2L13 23786 ● ● ● ATP2B1 490 ● ● ● BCL2L14 79370 ● ● ● ● ● ● ATP2B2 491 ● BCL2L2 599 ● ● ● ● ● ATP2B3 492 ● BCL3 602 ● ● ● ● ATP2B4 493 ● ● ● BCL6 604 ● ● ● ● ATP2C1 27032 ● ● ● ● ● BCL6B 255877 ● ● ● ● ● ATP4B 496 ● ● ● ● ● BCL7A 605 ● ● ● ATP5A1 498 ● ● ● BCL7B 9275 ● ● ● ● ● ● ATP5B 506 ● ● ● BCL7C 9274 ● ● ● ● ● ATP6V1H 51606 ● ● ● ● BCL9 607 ● ● ● ● ATR 545 ● ● ● ● BCL9L 283149 ● ● ● AURKB 9212 ● ● ● ● ● BCLAF1 9774 ● ● AURKC 6795 ● ● ● ● ● BDKRB1 623 ● ● ● ● ● ● AVEN 57099 ● ● ● ● BDKRB2 624 ● ● ● ● ● AVP 551 ● BDNF 627 ● ● ● ● ● ● AVPR1A 552 ● ● ● ● BECN1 8678 ● ● ● ● AVPR1B 553 ● ● BFAR 51283 ● ● ● ● ● AVPR2 554 ● ● BGLAP 632 ● ● ● ● ● ● AXIN1 8312 ● ● ● ● BICD1 636 ● ● ● AXL 558 ● ● ● ● ● ● ● ● BICD2 23299 ● AZGP1 563 ● ● ● ● BID 637 ● ● ● ● ● ● AZU1 566 ● ● BIK 638 ● ● ● ● ● B2M 567 ● ● ● ● ● ● ● BIN1 274 ● ● ● ● ● ● B3GALNT1 8706 ● ● ● BIN3 55909 ● ● ● ● ● ● B3GNT5 84002 ● ● BIRC2 329 ● ● ● ● B4GALT1 2683 ● ● BIRC3 330 ● ● ● ● ● BAALC 79870 ● ● ● ● ● BIRC5 332 ● ● ● ● ● ● ● ● BAD 572 ● ● ● ● ● ● BIRC6 57448 ● ● ● BAG1 573 ● ● ● ● ● ● ● BIRC7 79444 ● ● ● ● ● ● BAG2 9532 ● ● ● ● ● ● ● BIRC8 112401 ● ● ● ● ● BAG3 9531 ● ● ● ● BIVM 54841 ● BAG4 9530 ● ● ● ● ● ● BLCAP 10904 ● BAG5 9529 ● ● ● ● ● ● BLID 414899 ● ● ● ● ● ● BAG6 7917 ● ● ● ● ● ● BLK 640 ● ● ● ● ● ● ● 1. 3 ® ® B Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera BLM 641 ● ● ● ● C1QTNF1 114897 ● ● ● ● ● BLNK 29760 ● ● ● ● ● ● C1QTNF2 114898 ● ● ● ● ● ● C BLOC1S1 2647 ● ● C1QTNF3 114899 ● ● ● ● BLOC1S2 282991 ● C1QTNF4 114900 ● BMF 90427 ● ● C1QTNF5 114902 ● ● ● ● ● BMI1 648 ● ● ● ● ● C1QTNF6 114904 ● ● ● ● BMP1 649 ● ● ● ● ● C1QTNF7 114905 ● ● ● ● BMP10 27302 ● ● ● ● C1QTNF9 338872 ● ● BMP15 9210 ● C1R 715 ● ● ● BMP2 650 ● ● ● ● ● ● C1S 716 ● ● ● ● BMP3 651 ● ● ● ● ● C2 717 ● ● ● BMP4 652 ● ● ● C22orf28 51493 ● BMP5 653 ● ● ● ● ● ● ● C2CD2 25966 ● ● BMP6 654 ● ● ● ● ● C2CD2L 9854 ● ● BMP7 655 ● ● ● ● ● ● ● C3 718 ● ● ● ● ● BMP8A 353500 ● ● ● C3AR1 719 ● ● ● ● BMP8B 656 ● ● ● ● C3orf38 285237 ● ● BMPR1A 657 ● ● ● ● ● C3P1 388503 ● ● BMPR1B 658 ● ● ● ● ● ● ● C4A 720 ● ● BMPR2 659 ● ● ● ● ● C4B 721 ● ● ● ● BMX 660 ● ● ● ● C4BPA 722 ● ● ● BNIP1 662 ● ● ● ● ● C4BPB 725 ● ● ● ● ● ● BNIP2 663 ● ● C5 727 ● ● ● BNIP3 664 ● ● C5AR1 728 ● ● ● ● ● ● BNIP3L 665 ● ● ● ● ● ● C5orf13 9315 ● BNIPL 149428 ● ● ● ● C6 729 ● ● ● BOC 91653 ● ● ● C7 730 ● BOK 666 ● ● C7orf16 10842 ● ● ● ● BPIL3 128859 ● ● C8B 732 ● BRAF 673 ● ● ● ● C8G 733 ● BRCA1 672 ● ● ● ● ● C8orf4 56892 ● BRCA2 675 ● ● ● ● C9 735 ● ● ● BRE 9577 ● ● ● CACNA1A 773 ● BRMS1 25855 ● ● ● ● ● ● CACNB3 784 ● ● ● ● BRPF3 27154 ● ● CADM1 23705 ● ● ● ● ● BSG 682 ● ● ● ● ● ● CADM2 253559 ● BST1 683 ● ● ● ● ● CADM3 57863 ● ● BST2 684 ● ● ● ● ● ● CADM4 199731 ● BTBD9 114781 ● ● ● ● ● ● ● CADPS 8618 ● ●
Load more

Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Tools for Cell Therapy and Immunoregulation
    RnDSy-lu-2945 Tools for Cell Therapy and Immunoregulation Target Cell TIM-4 SLAM/CD150 BTNL8 PD-L2/B7-DC B7-H1/PD-L1 (Human) Unknown PD-1 B7-1/CD80 TIM-1 SLAM/CD150 Receptor TIM Family SLAM Family Butyrophilins B7/CD28 Families T Cell Multiple Co-Signaling Molecules Co-stimulatory Co-inhibitory Ig Superfamily Regulate T Cell Activation Target Cell T Cell Target Cell T Cell B7-1/CD80 B7-H1/PD-L1 T cell activation requires two signals: 1) recognition of the antigenic peptide/ B7-1/CD80 B7-2/CD86 CTLA-4 major histocompatibility complex (MHC) by the T cell receptor (TCR) and 2) CD28 antigen-independent co-stimulation induced by interactions between B7-2/CD86 B7-H1/PD-L1 B7-1/CD80 co-signaling molecules expressed on target cells, such as antigen-presenting PD-L2/B7-DC PD-1 ICOS cells (APCs), and their T cell-expressed receptors. Engagement of the TCR in B7-H2/ICOS L 2Ig B7-H3 (Mouse) the absence of this second co-stimulatory signal typically results in T cell B7-H1/PD-L1 B7/CD28 Families 4Ig B7-H3 (Human) anergy or apoptosis. In addition, T cell activation can be negatively regulated Unknown Receptors by co-inhibitory molecules present on APCs. Therefore, integration of the 2Ig B7-H3 Unknown B7-H4 (Mouse) Receptors signals transduced by co-stimulatory and co-inhibitory molecules following TCR B7-H5 4Ig B7-H3 engagement directs the outcome and magnitude of a T cell response Unknown Ligand (Human) B7-H5 including the enhancement or suppression of T cell proliferation, B7-H7 Unknown Receptor differentiation, and/or cytokine secretion.
    [Show full text]
  • Datasheet Blank Template
    SAN TA C RUZ BI OTEC HNOL OG Y, INC . LRP3 (E-13): sc-109956 BACKGROUND APPLICATIONS Members of the LDL receptor gene family, including LDLR (low density lipo- LRP3 (E-13) is recommended for detection of All LRP3 isoforms 1-3 of mouse, protein receptor), LRP1 (low density lipoprotein related protein), Megalin rat and human origin by Western Blotting (starting dilution 1:200, dilution (also designated GP330), VLDLR (very low density lipoprotein receptor) and range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution ApoER2 are characterized by a cluster of cysteine-rich class A repeats, epi - range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution dermal growth factor (EGF)-like repeats, YWTD repeats and an O-linked sugar range 1:30-1:3000); non cross-reactive with other LRP family members. domain. Low-density lipoprotein receptor-related protein 3 (LRP3) is a 770 LRP3 (E-13) is also recommended for detection of All LRP3 isoforms 1-3 in amino acid protein that contains two CUB domains and four LDL-receptor additional species, including equine, canine, bovine and porcine. class A domains. LRP3 is widely expressed with highest expression in skele - tal muscle and ovary and lowest expression in testis, colon and leukocytes. Suitable for use as control antibody for LRP3 siRNA (h): sc-97441, LRP3 LRP3 is potentially a membrane receptor involved in the internalization of siRNA (m): sc-149048, LRP3 shRNA Plasmid (h): sc-97441-SH, LRP3 shRNA lipophilic molecules and/or signal transduction. Plasmid (m): sc-149048-SH, LRP3 shRNA (h) Lentiviral Particles: sc-97441-V and LRP3 shRNA (m) Lentiviral Particles: sc-149048-V.
    [Show full text]
  • Expression Tissue
    The Journal of Immunology Killer Cell Ig-Like Receptor and Leukocyte Ig-Like Receptor Transgenic Mice Exhibit Tissue- and Cell-Specific Transgene Expression1 Danny Belkin,* Michaela Torkar,* Chiwen Chang,* Roland Barten,* Mauro Tolaini,† Anja Haude,* Rachel Allen,* Michael J. Wilson,* Dimitris Kioussis,† and John Trowsdale2* To generate an experimental model for exploring the function, expression pattern, and developmental regulation of human Ig-like activating and inhibitory receptors, we have generated transgenic mice using two human genomic clones: 52N12 (a 150-Kb clone encompassing the leukocyte Ig-like receptor (LILR)B1 (ILT2), LILRB4 (ILT3), and LILRA1 (LIR6) genes) and 1060P11 (a 160-Kb clone that contains ten killer cell Ig-like receptor (KIR) genes). Both the KIR and LILR families are encoded within the leukocyte receptor complex, and are involved in immune modulation. We have also produced a novel mAb to LILRA1 to facilitate expression studies. The LILR transgenes were expressed in a similar, but not identical, pattern to that observed in humans: LILRB1 was expressed in B cells, most NK cells, and a small number of T cells; LILRB4 was expressed in a B cell subset; and LILRA1 was found on a ring of cells surrounding B cell areas on spleen sections, consistent with other data showing monocyte/macrophage expression. KIR transgenic mice showed KIR2DL2 expression on a subset of NK cells and T cells, similar to the pattern seen in humans, and expression of KIR2DL4, KIR3DS1, and KIR2DL5 by splenic NK cells. These observations indicate that linked regulatory elements within the genomic clones are sufficient to allow appropriate expression of KIRs in mice, and illustrate that the presence of the natural ligands for these receptors, in the form of human MHC class I proteins, is not necessary for the expression of the KIRs observed in these mice.
    [Show full text]
  • Proteomic and Functional Characterisation of LILRA3: Role In
    Proteomic and Functional Characterisation of LILRA3: Role in Inflammation Terry Hung-Yi Lee A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Faculty of Medicine The University of New South Wales 2014 PLEASE TYPE THE UNIVERSITY OF NEW SOUTH WALES Thosis/Dissertatlon Sh09t Surname or Fam1ly name L l .... f.- First name / 'f (Z (1. 1 Other name/s H "'" ~ - \'I Abbre111at1on lor degree as given in the University calendar. Pt> .fh •I "!.1 '.j 17 J/ 0 School f t. t,...., ..> I <>f lVI e.~, u1 f <J t.r-UJ Faculty: M e. o1; c.• " e Tlrte Pr,te.;) ""l(. (j. f' il ,: ..... d .;" "' u"'"r &- d·er;..c&.L J .<\ ~ l/<.tf. Al: ~ " ' ~ ..... , ...., ~~~"""'" " "'~" Abstract 350 word s ma•imum: (PLEASE TYPE) Se e (f'JicJE' -------- Declaration relating to disposition of project thos tsldissortation I hereby grant to the Un1vers1ty of New South Wales or rts agents the nght to areh1ve and to make avatlabte my theSIS or dissertation '" whole or 1n part 1n the University libranes in all forms of media. now or here after known. subject to the provisions of the Copyright Act 1968 I retain all property nghts such as patent nghts I also retain the right to use in future works (such as artldes or bOOks) all or pan of this thesis or dlssenat1on I also authonse Un1vers1ty Microfilms to use the 350 word abstract of my thesis In Dissertation Abstracts International (this is appticable to doctoral ~~· ~l.A I Po .~.. <j 'I fJs JV VJignatur~ J1 Witness Date The Un1vers1ty recogn•ses that there may be exceptional circumstances requinng restrictions on copying or conditions on use.
    [Show full text]
  • Cleveland Clinic Laboratories
    Cleveland Clinic Laboratories Technical Update • May 2014 Cleveland Clinic Laboratories is dedicated to keeping you updated and informed about recent testing changes. That's why we are happy to provide this technical update on a monthly basis. Recently changed tests are bolded, and could include revisions to methodology, reference range, days performed or CPT code. For your convenience, tests are listed alphabetically and the order and billing codes are provided. If you wish to compare the new information with previous test demographics, refer to the Test Directory, which can be accessed at clevelandcliniclabs.com. Deleted tests and new tests are listed separately. Please update your database as necessary. For additional detail, contact Client Services at 216.444.5755 or 800.628.6816 or via email at [email protected]. Days Performed/Reported Specimen Requirement Special InformationComponent Change Test Discontinued Reference Range Test Update Name Change Methodology Order CodeBiling Code New Test Page # Summary of Changes CPT by Test Name 3 5-Hydroxyindolacetic Acid, Urine 3 11-Deoxycorticosterone Qt, Serum / Plasma 3 25-Hydroxyvitamin D2 and D3, Serum 9 Alpha-1 Antitrypsin (SERPINA1) Targeted Genotyping 3 Alpha-1-Antitrypsin Clearance 3 Alpha-1-Antitrypsin, Stool 3 Anti IgA Antibody 3 Anti Mullerian Hormone 3 Beta Galactosidase, Leukocytes 4 Bioavailable Testosterone / SHBG, Female & Child 4 BK Virus Quantitation, Urine 12 Buprenorphine & Metabolite, Confirmation / Quant, Urine 9 Buprenorphine Quant, Urine 4 Carnitine Free & Total,
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Identification of SH3 Domain Proteins Interacting with the Cytoplasmic Tail of the a Disintegrin and Metalloprotease 10 (ADAM10)
    Identification of SH3 Domain Proteins Interacting with the Cytoplasmic Tail of the A Disintegrin and Metalloprotease 10 (ADAM10) Henriette Ebsen, Marcus Lettau, Dieter Kabelitz, Ottmar Janssen* University of Kiel, Molecular Immunology, Institute for Immunology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany Abstract The a disintegrin and metalloproteases (ADAMs) play a pivotal role in the control of development, adhesion, migration, inflammation and cancer. Although numerous substrates of ADAM10 have been identified, the regulation of its surface expression and proteolytic activity is still poorly defined. One current hypothesis is that both processes are in part modulated by protein-protein interactions mediated by the intracellular portion of the protease. For related proteases, especially proline-rich regions serving as docking sites for Src homology domain 3 (SH3) domain-containing proteins proved to be important for mediating regulatory interactions. In order to identify ADAM10-binding SH3 domain proteins, we screened the All SH3 Domain Phager library comprising 305 human SH3 domains using a GST fusion protein with the intracellular region of human ADAM10 as a bait for selection. Of a total of 291 analyzed phage clones, we found 38 SH3 domains that were precipitated with the ADAM10-derived fusion protein but not with GST. We verified the binding to the cytosolic portion of ADAM10 for several candidates by co-immunoprecipitation and/or pull down analyses. Intriguingly, several of the identified proteins have been implicated in regulating surface appearance and/or proteolytic activity of related ADAMs. Thus, it seems likely that they also play a role in ADAM10 biology. Citation: Ebsen H, Lettau M, Kabelitz D, Janssen O (2014) Identification of SH3 Domain Proteins Interacting with the Cytoplasmic Tail of the A Disintegrin and Metalloprotease 10 (ADAM10).
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Supplementary Table S2
    1-high in cerebrotropic Gene P-value patients Definition BCHE 2.00E-04 1 Butyrylcholinesterase PLCB2 2.00E-04 -1 Phospholipase C, beta 2 SF3B1 2.00E-04 -1 Splicing factor 3b, subunit 1 BCHE 0.00022 1 Butyrylcholinesterase ZNF721 0.00028 -1 Zinc finger protein 721 GNAI1 0.00044 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 GNAI1 0.00049 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 PDE1B 0.00069 -1 Phosphodiesterase 1B, calmodulin-dependent MCOLN2 0.00085 -1 Mucolipin 2 PGCP 0.00116 1 Plasma glutamate carboxypeptidase TMX4 0.00116 1 Thioredoxin-related transmembrane protein 4 C10orf11 0.00142 1 Chromosome 10 open reading frame 11 TRIM14 0.00156 -1 Tripartite motif-containing 14 APOBEC3D 0.00173 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D ANXA6 0.00185 -1 Annexin A6 NOS3 0.00209 -1 Nitric oxide synthase 3 SELI 0.00209 -1 Selenoprotein I NYNRIN 0.0023 -1 NYN domain and retroviral integrase containing ANKFY1 0.00253 -1 Ankyrin repeat and FYVE domain containing 1 APOBEC3F 0.00278 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F EBI2 0.00278 -1 Epstein-Barr virus induced gene 2 ETHE1 0.00278 1 Ethylmalonic encephalopathy 1 PDE7A 0.00278 -1 Phosphodiesterase 7A HLA-DOA 0.00305 -1 Major histocompatibility complex, class II, DO alpha SOX13 0.00305 1 SRY (sex determining region Y)-box 13 ABHD2 3.34E-03 1 Abhydrolase domain containing 2 MOCS2 0.00334 1 Molybdenum cofactor synthesis 2 TTLL6 0.00365 -1 Tubulin tyrosine ligase-like family, member 6 SHANK3 0.00394 -1 SH3 and multiple ankyrin repeat domains 3 ADCY4 0.004 -1 Adenylate cyclase 4 CD3D 0.004 -1 CD3d molecule, delta (CD3-TCR complex) (CD3D), transcript variant 1, mRNA.
    [Show full text]